Overall, only 25.3% (95% CI: 16.7%, 33.8%) of patients experienced an IRR of any grade during the at‐home ocrelizumab infusion. These IRRs were 18.2% Grade 1 (95% CI: 10.6%, 25.8%) and 7.1% Grade 2 (95% CI: 2.9%, 14.0%); no IRRs were classified as ≥Grade 3 (95% CI: 0.0%, 3.7%) (Fig. Frequency of infusion‐related reactions experienced with home infusion by grade.IRR frequency by study cohort.IRR, infusion‐related reaction.